The Massachusetts and federal governments have been addressing the present opioid epidemic with both legislation and financial support. One piece of this ongoing effort is focused on a specific population: pregnant women with opioid substance use disorder. Grants have been awarded to researchers in MA, and collaboratives such as the MA Perinatal Quality Collaborative (MPQC) and MA Health Quality Partners (MHQP) have worked diligently to produce toolkits and guidelines to address care in pregnancy.
Due to these efforts, there has been significant work accomplished in MA in 2015. However, some leading this sentinel work in opioid substance use disorder in pregnant women have brought forward items that need to be addressed to action this work and provide responsible stewardship. Items identified to be addressed include: a) prevention of work/effort redundancies b) meaningful information dissemination and c) engagement of clinicians and communities.
In an attempt to bring together the ongoing work in maternal opioid substance use disorder in MA, MA ACOG convened a meeting of a statewide Maternal Opioid Advisory Group on Wednesday, March 16 from 4p-6:30p at the Massachusetts Medical Society in Waltham, MA. Recipients of MA grants, and leaders from MPQC, MMS and ACOG presented current information, toolkits, and regulatory information to help guide the agenda.
The goals of this meeting were very specific and included the following:
1) Share/distribute current best practices in maternal screening and identification of opioid substance use disorders
2) Identify treatment support that is currently available in communities statewide (to include treatment training and/or treatment referrals and support)
3) Identify the community support currently available (and identify improvement needs)
4) Identify neonatal support that is available (and identify improvement needs)
5) Identify legal and regulatory barriers that need to be mitigated for transparency in disease identification and treatment
6) Discuss strategies for dissemination of the information in 1 - 5
7) Discuss strategies for engagement of clinicians and communities in addressing 1 - 6
The Substance Abuse Sub-Comittee is chaired by Ron Iverson, MD, MPH